+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

KOL Perspectives: Implementation of the treat-to-target approach in IBD

  • ID: 4655670
  • Report
  • January 2018
  • Region: Global
  • 30 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie
  • Janssen
  • Prometheus
  • MORE
KOL Perspectives: Implementation of the treat-to-target approach in IBD

Summary

This KOL Insight briefing focuses on KOLs views of implementation of the treat-to-target approach in IBD.

The briefing includes analysis of KOL opinion on the following topic areas:
  • Perceptions of the CALM study and potential impact on Crohn’s disease clinical management
  • Adoption of a T2T approach in UC
  • Impact of T2T studies on choice of therapy
  • Monitoring mucosal healing in IBD
Key Highlights:
  • Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn’s disease
  • T2T is used routinely in clinical practice, with an increase in a patient’s disease severity used as a driver for adoption of the strategy
  • Over half the KOLs expect the CALM study to positively influence Crohn’s disease management across clinical practice.
Scope
  • The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)
  • In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based
  • Interviews performed during December 2017
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts.
Reasons to buy
  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "implementation of a treat-to-target (T2T) approach in IBD"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Janssen
  • Prometheus
  • MORE
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie
  • Prometheus
  • Janssen
Note: Product cover images may vary from those shown
Adroll
adroll